These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 33535836)
1. An update on drug development for the treatment of nonalcoholic fatty liver disease - from ongoing clinical trials to future therapy. Rau M; Geier A Expert Rev Clin Pharmacol; 2021 Mar; 14(3):333-340. PubMed ID: 33535836 [TBL] [Abstract][Full Text] [Related]
2. Current and new pharmacotherapy options for non-alcoholic steatohepatitis. Sumida Y; Yoneda M; Ogawa Y; Yoneda M; Okanoue T; Nakajima A Expert Opin Pharmacother; 2020 Jun; 21(8):953-967. PubMed ID: 32237916 [TBL] [Abstract][Full Text] [Related]
3. Current and future pharmacological therapies for NAFLD/NASH. Sumida Y; Yoneda M J Gastroenterol; 2018 Mar; 53(3):362-376. PubMed ID: 29247356 [TBL] [Abstract][Full Text] [Related]
4. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH). Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182 [TBL] [Abstract][Full Text] [Related]
5. FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid. Wang K; Zhang Y; Wang G; Hao H; Wang H Med Res Rev; 2024 Mar; 44(2):568-586. PubMed ID: 37899676 [TBL] [Abstract][Full Text] [Related]
6. Obeticholic acid for the treatment of nonalcoholic steatohepatitis. Shah RA; Kowdley KV Expert Rev Gastroenterol Hepatol; 2020 May; 14(5):311-321. PubMed ID: 32241197 [TBL] [Abstract][Full Text] [Related]
16. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice. Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284 [TBL] [Abstract][Full Text] [Related]
17. The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success. Drenth JPH; Schattenberg JM Expert Opin Investig Drugs; 2020 Dec; 29(12):1365-1375. PubMed ID: 33074035 [TBL] [Abstract][Full Text] [Related]
18. Emerging drugs for the treatment of hepatic fibrosis on nonalcoholic steatohepatitis. Iwaki M; Yoneda M; Wada N; Otani T; Kobayashi T; Nogami A; Saito S; Nakajima A Expert Opin Emerg Drugs; 2024 Jun; 29(2):127-137. PubMed ID: 38469871 [TBL] [Abstract][Full Text] [Related]
19. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Adorini L; Pruzanski M; Shapiro D Drug Discov Today; 2012 Sep; 17(17-18):988-97. PubMed ID: 22652341 [TBL] [Abstract][Full Text] [Related]
20. Evolving Role for Pharmacotherapy in NAFLD/NASH. Attia SL; Softic S; Mouzaki M Clin Transl Sci; 2021 Jan; 14(1):11-19. PubMed ID: 32583961 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]